This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Psychosis; emotional lability	NMDA receptor NR2A subtype (GRIN2A; NR2A); GRIN2B (NR2B)	<p>Mouse studies suggest NR2A and NR2B antagonists could help treat aggressive behavior. Humans and mice with a monoamine oxidase A (MAO-A) deficiency show aggressive outbursts in response to stress. In <i>Mao-a</i>-deficient mice, NR2A- or NR2B-selective NMDAR antagonists decreased aggression compared with saline. Next steps include dose-ranging studies in animal models. At least 17 companies have NMDAR antagonists on the market or in development to treat neurological and psychiatric indications.</p> <p>SciBX 5(29); doi:10.1038/scibx.2012.764 Published online July 26, 2012</p>	Unpatented; licensing status not applicable	<p>Bortolato, M. <i>et al. J. Neurosci.</i>; published online June 20, 2012; doi:10.1523/JNEUROSCI.0225-12.2012 Contact: Jean C. Shih, University of Southern California, Los Angeles, Calif. e-mail: jcshih@usc.edu Contact: Marco Bortolato, same affiliation as above e-mail: bortolat@usc.edu</p>